Estrogen and progestin use and the QT interval in postmenopausal women

被引:73
|
作者
Kadish, AH
Greenland, P
Limacher, MC
Frishman, WH
Daugherty, SA
Schwartz, JB
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Dept Internal Med, Chicago, IL USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL USA
[4] Univ Florida, Coll Med, Div Cardiol, Gainesville, FL USA
[5] New York Med Coll, Dept Med, Valhalla, NY USA
关键词
electrocardiology; sex hormones;
D O I
10.1111/j.1542-474X.2004.94580.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether menopausal hormone therapy alters the QT interval in primarily healthy postmenopausal women. Background: Despite well-known gender differences in myocardial repolarization that include a longer heart-rate-corrected QT interval (QT(C)) in women compared to men, the effects of menopausal hormone therapy on myocardial repolarization in women have not been well characterized. Methods: We studied 34,378 postmenopausal women participating in the dietary intervention component of the Women's Health Initiative. Cross-sectional associations were examined to assess possible effects of estrogen + progesterone on myocardial repolarization. Women who reported that they were never treated with menopausal hormone therapy (n = 12,451) were compared to women with a past use of menopausal hormone therapy (n = 3891), currently taking unopposed estrogen therapy (n = 9987), or combined current estrogen and progesterone therapy (n = 8049). Results: Using analysis of covariance, the mean (+/-SEM) QT(C) interval was 423.9 +/- 0.3 milliseconds (ms) in those never treated with menopausal hormone therapy, 423.9 +/- 0.3 ms in past menopausal hormone therapy users, 425.6 +/- 0.2 ms in those currently on estrogen alone, and 424.0 +/- 0.2 ms in women currently on combined estrogen-progesterone therapy. Differences in mean QT(C) between those on estrogen alone and the other three groups were statistically significant. Comparisons of JT intervals, QT intervals, and linear corrected QT intervals among the groups yielded similar results. Conclusion: These results suggest that unopposed estrogen in menopausal women mildly prolongs myocardial repolarization, and the effect is reversed by progesterone. Whether these findings have clinical significance requires further study.
引用
收藏
页码:366 / 374
页数:9
相关论文
共 50 条
  • [1] Effects of progestin-estrogen replacement therapy on QT-dispersion in postmenopausal women
    Haseroth, K
    Seyffart, K
    Wehling, M
    Christ, M
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 75 (2-3) : 161 - 165
  • [2] Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
    Chlebowski, Rowan T.
    Kuller, Lewis H.
    Prentice, Ross L.
    Stefanick, Marcia L.
    Manson, Joann E.
    Gass, Margery
    Aragaki, Aaron K.
    Ockene, Judith K.
    Lane, Dorothy S.
    Sarto, Gloria E.
    Rajkovic, Aleksandar
    Schenken, Robert
    Hendrix, Susan L.
    Ravdin, Peter M.
    Rohan, Thomas E.
    Yasmeen, Shagufta
    Anderson, Garnet
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06): : 573 - 587
  • [3] Breast cancer outcome and estrogen plus progestin use in postmenopausal women
    Chiebowski, R. T.
    Anderson, G. L.
    Gass, M.
    Lane, D. S.
    Aragaki, A. K.
    Kuller, L. H.
    Manson, J. E.
    Stefanick, M. L.
    Ockene, J.
    Prentice, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Can we measure prior Postmenopausal Estrogen/Progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial
    Greendale, GA
    James, MK
    Espeland, MA
    BarrettConnor, E
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1997, 146 (09) : 763 - 770
  • [6] Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women
    Olof J. Kjartansdottir
    Lara G. Sigurdardottir
    Elinborg J. Olafsdottir
    Jon G. Jonasson
    Giske Ursin
    Laufey Tryggvadottir
    Breast Cancer Research and Treatment, 2017, 163 : 363 - 373
  • [7] Estrogen plus progestin and colorectal cancer in postmenopausal women
    Chlebowski, RT
    Wactawski-Wende, J
    Ritenbaugh, C
    Hubbell, FA
    Ascensao, J
    Rodabough, RJ
    Rosenberg, CA
    Taylor, VM
    Harris, R
    Chen, C
    Adams-Campbell, LL
    White, E
    Alving, B
    Rossouw, J
    Pottern, L
    Ludlam, S
    McGowan, J
    Prentice, R
    Anderson, G
    LaCroix, A
    Patterson, R
    McTiernan, A
    Cochrane, B
    Hunt, J
    Tinker, L
    Kooperberg, C
    McIntosh, M
    Wang, CY
    Chen, C
    Bowen, D
    Kristal, A
    Stanford, J
    Urban, N
    Weiss, N
    White, E
    Shumaker, S
    Rautaharju, P
    Prineas, R
    Naughton, M
    Stein, E
    Laskarzewski, P
    Cummings, S
    Nevitt, M
    Dockrell, M
    Harnack, L
    Cammarata, F
    Lindenfelser, S
    Psaty, B
    Heckbert, S
    Wassertheil-Smoller, S
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10): : 991 - 1004
  • [8] Estrogen plus progestin and colorectal cancer in postmenopausal women
    Grant, ECG
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2417 - 2418
  • [9] CONTINUOUS ESTROGEN-PROGESTIN THERAPY IN POSTMENOPAUSAL WOMEN
    SALPETER, S
    WESTERN JOURNAL OF MEDICINE, 1989, 151 (05): : 542 - 543
  • [10] Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
    Darling, GM
    Johns, JA
    McCloud, PI
    Davis, SR
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09): : 595 - 601